(1) To evaluate the effectiveness of anti-resorptive drug therapies for primary and secondary prevention of fractures in ‘real world’ subjects.
(2) To determine to what extent the current osteoporosis management is ensuring that patients with osteoporosis are appropriately treated in Australia
(3) To assess the impact of anti-resorptive drug therapies on mortality and the implication for cost-benefit analysis of anti-osteoporosis therapies
(4) To examine the association between different types of fracture and mortality and identify any factors that may predict premature mortality
(5) To investigate adverse drug reaction incidence (including cancers) with short term and long term uses of various anti-resorptive drug therapies
(6) To identify drugs with adverse skeletal effects and their interaction with anti-resorptive drug therapies